Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Cell Therapy
Low Disease Burden Improved Durability of CAR T-Cell Therapy in B-ALL – Cancer Network
Posted: April 4, 2017 at 1:47 am
Although most adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL) experienced complete remission after treatment with 19-28z chimeric antigen receptor (CAR) T cells, those patients with a low pretreatment disease burden experienced a more durable remission, according to results (abstract CT078) presented at the American Association for Cancer Research (AACR) Annual Meeting 2017, held April 15 in Washington, DC.
Our data suggest that incorporation of 19-28z CAR T cells at the time of minimal residual disease [MRD] following first-line chemotherapy will maximize the durability of CAR T-cell mediated remissions and survival and can potentially spare these high-risk patients from hematopoietic stem cell transplant [HSCT], rather than waiting until they relapse morphologically and then trying CAR T-cell therapy when it is less likely to achieve a durable long-term outcome, said Jae Park, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, in a press release.
According to Park, survival among adults with relapsed or refractory ALL is extremely poor. In order to develop more effective therapies for these patients, Park and others have developed and tested CD19-specific CAR T-cell therapy. This treatment has demonstrated high initial responses in patients with relapsed B-ALL; however, more data were needed to define clinical characteristics of patients who experience greater durability of response.
In this study, 51 patients received 19-28z CAR T cells. The researchers assessed disease burden by bone marrow biopsy immediately prior to T-cell infusion. Patients were grouped into two cohorts: MRD with less than 5% blasts in bone marrow; and morphologic disease (5% or greater blasts).
The two groups had similar rates of complete remission: 95% for the MRD cohort and 77% for the morphologic cohort.
However, when the researchers analyzed survival by cohort, they found that patients with MRD had significantly improved survival outcomes. The median event-free survival for MRD-negative patients with complete remission was not yet reached compared with 6.3 months for the morphologic group (P = .0005). Similarly, the median overall survival was not yet reached for the MRD group compared with 17 months for the morphologic group (P = .0189).
Subsequent transplant was found to have no effect on survival regardless of the patient cohort.
While more patients and longer follow-up will be needed to adequately address the significance of HSCT, the result of this analysis raises a question as to whether 19-28z CAR therapy can be considered as a definitive, curative therapy rather than a bridge to stem cell transplant, at least in a subset of patients, Park said.
Patients from the MRD cohort fared well in terms of side effects as well, compared with those in the morphologic disease cohort. Two of the major side effects associated with CAR T cells, cytokine release syndrome and neurotoxicity, occurred in 42% and 58% of the patients, respectively, in the morphologic disease cohort, compared with 5% and 15%, respectively, in those from the MRD cohort.
The rest is here:
Low Disease Burden Improved Durability of CAR T-Cell Therapy in B-ALL - Cancer Network
Posted in Cell Therapy
Comments Off on Low Disease Burden Improved Durability of CAR T-Cell Therapy in B-ALL – Cancer Network
Premier Wellness Group Offers Regenerative Cell Therapy for Knee … – GlobeNewswire (press release)
Posted: April 3, 2017 at 6:46 am
April 02, 2017 10:00 ET | Source: Premier Wellness Group
CAPE CORAL, Fla., April 02, 2017 (GLOBE NEWSWIRE) -- Regenerative cell therapy offers residents a way to reduce pain and support their bodys healing process from auto accident injuries, personal injuries, and sports injuries. Painful acute and chronic injuries can be healed using amniotic stem cells. Patients can experience pain relief without drugs with regenerative cell therapy injections that use the growth factors in amniotic stem cells to stimulate healing. Regenerative cell therapy can allow patients a safe form of pain relief and reduce their reliance on pain medications. Regenerative cell therapy is available as part of a patients individualized treatment program by the medical team at Premier Wellness Group.
Regenerative stem cell therapy offers pain relief for auto accident injuries and personal injuries, such as patients dealing with shoulder pain, knee pain, and back pain. Stem cells are a powerful tool for healing. The specialized cells begin as blank cells in that they can be used to regrow any cell needed. It is possible to regrow new cells, muscle, and tissue without surgery. Uninjured stem cells are injected into a targeted area and develop into needed cells. Stem cell therapy supports the bodys own healing process, allowing patients to benefit from injury management without surgery or painkillers.
Patients do not need to worry about any reactions due to rejection, and the amniotic regenerative stem cell therapy process is the least evasive of other forms of stem cell therapy. Patients need little, if any, downtime and stem cell therapy complements chiropractic treatments, massage therapy, nutritional counseling, and corrective exercises to guide the body back into a state of wellness. Stem cell therapy can reduce inflammation, promote healing, and increase range of motion.
We are pleased to provide patients with a natural form of pain relief and rehabilitation that takes into account the bodys own ability to heal itself, said Dr. Patrick King. Regenerative cell therapy requires no surgery- only injections performed by our physician. Stem cell therapy is safe and most patients require no downtime. We invite residents suffering from pain or trauma due to a car accident injury, sports injury, or personal injury to contact our team to learn more about this advanced therapy for healing and recovery.
Dr. Patrick King, clinic director and owner of Premier Wellness Group, has served the chiropractic and rehabilitation needs of residents of Cape Coral, Fort Myers, and surrounding communities for more than 15 years. Patients have made Premier Wellness Group their destination for drug-free, non-surgical pain relief, and rehabilitation. Services at Premier Wellness Group include regenerative cell therapy, trigger point therapy, corrective exercises, lifestyle recommendations, and chiropractic care.
Call (239) 573-7988 to learn more about Cape Coral regenerative cell therapy for knee and shoulder pain relief, or to schedule an appointment. Visit http://www.mypremierwellnessgroup.com/ for additional details.
Related Articles
View original post here:
Premier Wellness Group Offers Regenerative Cell Therapy for Knee ... - GlobeNewswire (press release)
Posted in Cell Therapy
Comments Off on Premier Wellness Group Offers Regenerative Cell Therapy for Knee … – GlobeNewswire (press release)
Ynetnews Culture – Stem-cell therapy: The medicine of the future – Ynetnews
Posted: March 31, 2017 at 3:47 am
In one of the famous scenes of American animated sitcom Family Guy, which was aired on January 2008, the main character, Peter Griffin, is seen entering a stem cell research lab with half his body paralyzed, as a result of a stroke, and walking out completely healthy.
Growing a heart on a plate (PR photo)
Imagination plays an important role in dealing with stem cells. Theoretically, cells that, in a lab, can differentiate into any specialized cell present countless options of playing with the human bodyfrom treating any physical medical failure, through preparing a bank of human spare parts, to producing a new race of perfect human beings, completely flawless and immune. That is only in theory, however, at least at this stage. In practice, the possibilities inherent in stem cells are still imaginary, and using them for actual treatment is still very limited.
Torontos skyline is dotted with multi-story buildings, each with a series of elevators that fly visitors within second from the ground floor to the upper floors. The 35th floor of Eaton Centre, a shopping mall and office complex located near Dundas Squarewhich locals say is like Times Square, only a lot less impressiveoverlooks almost all parts of the Ontario provinces capital.
Using stem cells for the sake of humanity (Illustration photo: Shutterstock)
The most fascinating research has to do with cardiology. This is the field in which the ability to imagine a new era in the near future appears most palpable. Its difficult to overstate the complexity of the human heart, which is made up of different types of cells and tissues and is activated through a sequence of electrical pulses. Modern medicine has been unsuccessful so far in creating an industrial alternative for the heart, at least not one that allows a quality of life, while transplant surgery suffers from the risks of transplant rejection and a regular donor shortage. These limitations, in addition to the fact that heart diseases are very common and are one of the leading causes of death around the world, make cardiology a fertile ground for an industry of innovative medicine.
PR photo
One field in which this vision has already become a reality, at least partially, is lung therapy. Stem cell medicine holds a potential in terms of lungs suitable for transplantation, when it comes to improving of the chances that the new body wont reject the organ. The entire process, however, is complicated. Lung transplantation is only possible when the person who agreed to donate his organs in advance is declared brain dead, which makes it possible to harvest the organs before the entire body collapses, and these are pretty specific cases. In addition, in this group only 20 percent of the donated lungs are eventually transplantedas the procedure must be quick, and in most cases doctors dont have sufficient information about the lungs condition and the ability to prepare it for a transplantation which wont be rejected.
PR photo
In the stem-cell therapy labs in Toronto, the future is both present and absent. Most researchers refuse to fall into the press trap and talk about a vision for a better future in which every problem will be treated by injecting stem cells. And although the phrase growing a heart on a plate is occasionally heard, they make sure to clarify that such a situation is still far off. Nevertheless, no one will deny that stem-cell therapy is the medicine of the future.
The combination of medical and technological innovations may have brought humanity to the start of a new era, in which it will be possible to cure the body in an immensely more efficient way than in the past. But even these accomplishments highlight how little we know about the human body and how much more we need to learn and work in order to be able to unlock the full potential hiding deep within our cells.
(Translated and edited by Sandy Livak-Furmanski)
Continued here:
Ynetnews Culture - Stem-cell therapy: The medicine of the future - Ynetnews
Posted in Cell Therapy
Comments Off on Ynetnews Culture – Stem-cell therapy: The medicine of the future – Ynetnews
Stem cell therapy for restoring erectile function – BSI bureau (press release)
Posted: March 31, 2017 at 3:47 am
About thirty percent of the patients reported full improvement which was maintained over a period of one year.
A stem cells based technique has been established by a team of researchers from Odense University Hospital in Denmark, as a cure for erectile dysfunction.
Erectile dysfunction is a problem being encountered by nearly half of the men between the age groups of 40 and 70 years. High blood pressure, diabetes, cardiovascular diseases, psychological problems are a few causes responsible for this disorder in men.
As a cure, men are often advised medications, injection and penile implants to help solve this problem. But these methods have certain disadvantages. Researchers have been looking into devising a more safe and definite method for addressing this problem.
As part of a new research, man's own fat stem cells were isolated, and injected into the corpus cavernosum area of the penis. About thirty percent of the patients reported full improvement which was maintained over a period of one year.
The researchers are now planning to conduct next round of trial to evaluate the effectiveness and safety of this new technique.
Originally posted here:
Stem cell therapy for restoring erectile function - BSI bureau (press release)
Posted in Cell Therapy
Comments Off on Stem cell therapy for restoring erectile function – BSI bureau (press release)
Novartis says US regulator grants speedy review of CAR-T cell therapy – Fox News
Posted: March 30, 2017 at 1:40 pm
ZURICH Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its review of the Swiss drugmaker's CTL019 therapy for young patients with B-cell acute lymphoblastic leukemia.
The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers.
ZARA FOUNDER TO SPEND $344M ON BREAST CANCER-SCREENING FOR SPANISH HOSPITALS
The therapy involves a patient's own T-cells being altered in the lab to help the immune system find and kill cancer cells before being re-infused into the patient.
Basel-based Novartis' first CAR-T therapy license application with the FDA has put the company in pole position with regulators as it pushes for approval alongside rivals including biotech Kite Pharma Inc that are developing similar therapies.
"With CTL019, Novartis is at the forefront of the science and development of immunocellular therapy as a potential new innovative approach to treating certain cancers where there are limited options," Vas Narasimhan, Novartis head of drug development, said in a statement.
CTL019 will likely cost hundreds of thousands of dollars per patient if approved, and Novartis counts it among drugs it believes will eventually exceed $1 billion in annual sales.
DEVON AND LEAH STILL CELEBRATE TWO YEARS IN REMISSION
In a Phase II study, Novartis said 82 percent of patients infused with CAR-T cells achieved complete remission or complete remission with incomplete blood count recovery at three months after treatment. In December, Novartis estimated that 60 percent of those responders were relapse-free after six months.
The company plans to submit an application for market authorization with the European Medicines Agency (EMA) later this year.
See the original post:
Novartis says US regulator grants speedy review of CAR-T cell therapy - Fox News
Posted in Cell Therapy
Comments Off on Novartis says US regulator grants speedy review of CAR-T cell therapy – Fox News
Interferon-beta producing stem cell-derived immune cell therapy on … – Science Daily
Posted: March 29, 2017 at 2:44 am
All causes of the most common form of liver cancer, hepatocellular carcinoma (HCC), are not yet known, but the risk of getting it is increased by hepatitis B or C, cirrhosis, obesity, diabetes, a buildup of iron in the liver, or a family of toxins called aflatoxins produced by fungi on some types of food. Typical treatments for HCC include radiation, chemotherapy, cryo- or radiofrequency ablation, resection, and liver transplant. Unfortunately, the mortality rate is still quite high, with the American Cancer Society giving a 5-year survival rate for localized liver cancer at 31%.
Hoping to improve primary liver cancer including HCC and metastatic liver cancer therapies, researchers from Japan began studying induced pluripotent stem (iPS) cell-derived immune cells that produced the protein interferon-? (IFN-). IFN- exhibits antiviral effects related to immune response, and two different antitumor activities, the JAK-STAT signaling pathway and p53 protein expression. IFN- has been used for some forms of cancer but problems like rapid inactivation, poor tissue penetration, and toxicity have kept it from being used extensively. To get over that hurdle, Kumamoto University researchers used iPS cell-derived proliferating myelomonocytic (iPS-ML) cells, which they developed in a previous research project. These cells were found to mimic the behavior of tumor associated macrophages (TAMS), which inspired the researchers to develop them as a drug delivery system for IFN- and evaluate the therapeutic effect on liver cancer in a murine model in vivo.
The researchers selected two cancer cell lines that were sensitive to IFN- treatment, one that easily metastasized to the liver after injection into the spleen and the other that produced a viable model after being directly injected into the liver. After injection, mice that tested positive for cancer (~80%) were separated into test and control groups. iPS-ML/IFN- cells were injected two to three times a week for three weeks into the abdomen of the test groups.
Livers with tumors were found to have higher levels of IFN- than those without. This was likely due to iPS-ML/IFN- cells penetrating the fibrous connective tissue capsule surrounding the liver ?serous membrane?and migrating toward intrahepatic cancer sites. The iPS-ML/IFN- cells did not penetrate non-tumorous livers, but rather stayed on the surface of the organ. Furthermore, concentrations of IFN- from 24 to 72 hours after iPS-ML/IFN- injections were found to be high enough to inhibit proliferation or even cause the death of the tumor cells.
Due to differences between species, mouse cells are not adversely affected by human IFN-, meaning that side effects of this treatment are not visible in this model. Fortunately, the researchers are working on a new model with the mouse equivalent of human iPS-ML/IFN, and testing its therapeutic abilities.
"Our recent research into iPS-cell derived, IFN- expressing myeloid cells should be beneficial for many cancer patients," says research leader Dr. Satoru Senju. "If it is determined to be safe for human use, this technology has the potential to slow cancer progression and increase survival rates. At this point, however, we still have much work ahead."
This research may be found in the Journal of Hepato-Biliary-Pancreatic Sciences online.
Story Source:
Materials provided by Kumamoto University. Note: Content may be edited for style and length.
View post:
Interferon-beta producing stem cell-derived immune cell therapy on ... - Science Daily
Posted in Cell Therapy
Comments Off on Interferon-beta producing stem cell-derived immune cell therapy on … – Science Daily
Cell Therapy Manufacturing Market, 2027: Partnerships / Collaborations have been Widespread and will Continue to … – GlobeNewswire (press release)
Posted: March 29, 2017 at 2:44 am
March 28, 2017 10:55 ET | Source: Research and Markets
Dublin, March 28, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Cell Therapy Manufacturing Market, 2017-2027" report to their offering.
During the course of our study, we identified over 110 organizations that are actively involved in the manufacturing of cell therapies.
The scope of this report primarily includes manufacturing of advanced therapy medicinal products (ATMPs) that involve the use of immune cells such as T-cells, Tregs, dendritic cells, tumor cells and NK cells, and stem cells such as adult stem cells, human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).
Several players, including cell therapy developers, research institutes, contract manufacturing organizations, and government and non-profit organizations, are playing a critical role in the development and manufacturing of these cell therapies. In fact, a number of these players have made heavy investments to expand their existing capabilities and establish new facilities for cell therapy products in order to meet the increasing demand.
Additionally, stakeholders have received significant support from governments worldwide, in terms of funding and establishment of consortiums to accelerate the transition of these therapies from laboratories to clinics. It is important to highlight that companies that offer logistics and operational services have developed systems / tools for safer and quicker delivery of therapies from manufacturing sites to patients; this has been identified as one of the key challenges in the overall development process.
Popular examples of approved cell-based therapies include (in order of their year of approval) Carticel, CreaVax-RCC, JACE, ReliNethra, PROVENGE and Prochymal. In addition, over 500 cell-based therapy candidates are currently in different stages of clinical development; these are being evaluated in over 1,000 active clinical studies in various regions across the globe. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development, continues to create an increasing demand for facilities that offer manufacturing services for these therapies.
The market already has a wide array of well-established players, mid-sized companies and start-ups. Several industry players as well as academic institutes are significantly contributing to the production of GMP grade cell types. In addition, the market has witnessed the entry of several players that offer novel technology solutions, aimed at improving and upgrading existing cell-based therapies and their manufacturing processes. We have observed that such players have signed multiple partnerships / collaborations with an aim to optimize, scale-up and expand the capabilities for production of cell-based therapies.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. CELL THERAPY MANUFACTURING: INTRODUCTION 3.1. Context and Background 3.2. Cell-based Therapies: Introduction 3.3. Cell Therapy Manufacturing: An Introduction 3.4. Cell-based Therapies Manufacturing: Key Challenges 3.5. Cell Therapy Manufacturing: Types of Manufacturers 3.6. Cell Therapy Manufacturing: Other Important Considerations 3.7. Cell Therapy Manufacturing: Regulatory Landscape
4. MARKET OVERVIEW 4.1. Chapter Overview 4.2. Cell Therapy Manufacturing: Overall Market Landscape 4.3. Cell Therapy Manufacturing: Role of Logistic Service Providers
5. ROADMAPS: POTENTIAL STRATEGIES TO OVERCOME EXISTING CHALLENGES 5.1. Chapter Overview 5.2. Roadmap for the United States 5.3. Roadmaps for Other Geographies
6. CELL THERAPY MANUFACTURING: IN-HOUSE MANUFACTURERS 6.1. Chapter Overview 6.2. Argos Therapeutics 6.3. Bavarian Nordic 6.4. Cytori Therapeutics 6.5. Juno Therapeutics 6.6. MEDIPOST 6.7. SOTIO (Acquired by PPF Group) 6.8. Stemedica Cell Technologies
7. CELL THERAPY MANUFACTURING: INDUSTRY PLAYERS 7.1. Chapter Overview 7.2. Cell and Gene Therapy Catapult 7.3. CELLforCURE 7.4. Lonza 7.5. PharmaCell 7.6. PCT, a Caladrius Company 7.7. Roslin Cell Therapies 7.8. Waisman Biomanufacturing
8. CELL THERAPY MANUFACTURING: NON-INDUSTRY PLAYERS 8.1. Chapter Overview 8.2. Center for Cell and Gene Therapy, Baylor College of Medicine, US 8.3. Centre for Cell Manufacturing Ireland, National University of Ireland, Ireland 8.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania, US 8.5. Guy's And St. Thomas' GMP Facility, Guy's Hospital, UK 8.6. Newcastle Cellular Therapies Facility, Newcastle University, UK 8.7. Rayne Cell Therapy Suite, King's College London, UK 8.8. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre of Regenerative Medicine, UK 8.9. Laboratory of Cell and Gene Medicine, Stanford University, US
9. ROLE OF NON-PROFIT ORGANIZATIONS 9.1. Chapter overview 9.2. Cell Therapy Manufacturing: List of Non-Profit Organizations 9.3. Cell Therapy Manufacturing: International Societies
10. RECENT DEVELOPMENTS 10.1. Chapter Overview 10.2. Collaboration / Agreement Models 10.3. Cell Therapy Manufacturing: List of Collaborations 10.4. Cell Therapy Manufacturing: Partnership Analysis
11. MARKET SIZING AND FORECAST 11.1. Context and Background 11.2. Forecast Methodology 11.3. Cell Therapy Manufacturing Market, 2017-2027 11.4. Cell Therapy Manufacturing Market: Regional View
12. SWOT ANALYSIS
13. CONCLUSION 13.1. A Growing Pipeline of Cell Therapy Products is Likely to Increase the Demand for Manufacturing of Cell-based Therapies 13.2. Stakeholders are Continuously Striving to Overcome Existing Challenges 13.3. Developed Economies have Emerged as Prominent Hubs for Cell Therapy Manufacturing 13.4. Both Industry and Academia have Jointly Led the Initiatives; The Trend is Likely to Persist in the Near Term 13.5. Partnerships / Collaborations have been Widespread and will Continue to act as Key Enablers 13.6. The Manufacturing of Cell-based Therapies is Likely to Become a Multi-billion Dollar Market in the Coming Decade
14. SURVEY ANALYSIS 14.1. Chapter Overview 14.2. Seniority Level of Respondents 14.3. Type of Cell Therapy 14.4. Scale of Operation 14.5. Source of Cells 14.6. Type of Cell Culture System 14.7. Fill / Finish Service
15. INTERVIEW TRANSCRIPTS 15.1. Chapter Overview 15.2. Tim Oldham, CEO, Cell Therapies 15.3. Brian Dattilo, Manager of Business Development, Waisman Biomanufacturing 15.4. Mathilde Girard, Department Leader, Cell Therapy Innovation and Development, YposKesi 15.5. Dr. Gerard J Bos (CEO, CiMaas)
16. APPENDIX: TABULATED DATA
17. APPENDIX: LIST OF COMPANIES AND RESEARCH ORGANIZATIONS
For more information about this report visit http://www.researchandmarkets.com/research/bvlctq/cell_therapy
Related Articles
Go here to read the rest:
Cell Therapy Manufacturing Market, 2027: Partnerships / Collaborations have been Widespread and will Continue to ... - GlobeNewswire (press release)
Posted in Cell Therapy
Comments Off on Cell Therapy Manufacturing Market, 2027: Partnerships / Collaborations have been Widespread and will Continue to … – GlobeNewswire (press release)
Replicel’s cell therapy candidate RCT-01 shows treatment effect in patients with degenerated Achilles tendon – Seeking Alpha
Posted: March 29, 2017 at 2:44 am
Results from an eight-subject Phase 1/2 clinical trial, ReaCT, assessing a single injection of Replicel Life Sciences' (OTCQB:REPCF) RCT-01 into the Achilles tendon of patients with Achilles tendinosis showed clinically important improvements including pain sensation, physical function, blood supply and tendon composition.
Achilles tendinosis is a degenerative process of the tendon that does to present with signs like inflammation either clinically or by examining tissue samples under a microscope, but is associated with pain and loss of function. There are no effective therapies for the condition.
Participants showed clinically relevant signs of healing six months after injection as measured by an overall 15.3% improvement in a scale called VISA-A. Two patients achieved almost total recovery. Four of five patients who completed questionnaires showed relevant signs of improvement in pain on loading (running/jumping) based on a scale called VAS. The average improvement in VAS score from baseline was 62.9%. Three of the five patients experienced improvements in pain on palpation (feeling the tendon with the hands during a physical exam). The average improvement in VAS score from baseline was 55.2%.
All study participants except one experienced at least one adverse event, either injection site soreness or observation of a partial thickness tear in the tendon after the injection.
RCT-01 is an autologous cell therapy that uses non-bulbar dermal sheath cells isolated from the hair follicle sheath. Developmentis ongoing.
Here is the original post:
Replicel's cell therapy candidate RCT-01 shows treatment effect in patients with degenerated Achilles tendon - Seeking Alpha
Posted in Cell Therapy
Comments Off on Replicel’s cell therapy candidate RCT-01 shows treatment effect in patients with degenerated Achilles tendon – Seeking Alpha
Nohla and UC Davis Ink Manufacturing Deal for Off-the-Shelf Donor Stem Cell Therapy – Genetic Engineering & Biotechnology News
Posted: March 29, 2017 at 2:44 am
Nohla Therapeutics is tapping the University of California, Davis (UC Davis) for its expertise in cell therapy GMP and manufacturing so that it can scale up clinical trials manufacture of NLA101, Nohla's Phase IIb-stage off-the-shelf universal donor stem and progenitor cell therapy for hematologic cancers. The firm will also work with UC Davis to further optimize the NLA101 manufacturing process, with a view to future commercial production.
Under terms of the collaboration and manufacturing agreement, UC Davis will carry out manufacturing and quality control testing of NLA101 at the UC Davis Institute of Regenerative Cures (IRC) cGMP Cell Therapy Manufacturing Facility in Sacramento, CA. Nohla has sublicensed office and laboratory space at the Oak Park Research Center next to the IRC, which will act as a warehouse and distribution center for supplying the IRC with raw materials and for storing NLA101 for distribution to the clinical trials sites. The collaboration will enable the production of enough NLA101 to supply clinical trials evaluating NLA101 in hematopoietic cell transplant and for treating chemotherapy-induced neutropenia.
This collaboration allows Nohla to capitalize on the expertise at UC Davis to scale manufacturing for NLA101 and increase our ability to supply product for multiple clinical trials, commented Kathleen Fanning, president and CEO at Nohla.
Lars Berglund, M.D., Ph.D., associate vice chancellor for biomedical research and vice dean for research at UC Davis School of Medicine, added, We are particularly excited to partner with Nohla for the development of this groundbreaking technology as it demonstrates our commitment to work with innovative companies developing lifesaving therapies.
Nohla was established in 2015 to exploit technology developed at the Fred Hutchinson Cancer Research Center, which enables the Notch-mediated ex vivo expansion and directed differentiation of cord blood stem and progenitor cells into off-the-shelf universal donor cell therapies that can be used on demand without human leukocyte antigen (HLA) matching in recipients.
The lead product NLA101 has been evaluated in more than 100 patients at high risk of severe infection and other complications after chemotherapy or cord blood transplantation. A Phase IIb study is ongoing in patients undergoing myeloablative cord blood transplant for leukemia and other blood cancers. Nohla is also planning to start a Phase II study in patients undergoing high-dose chemotherapy for acute myelogenous leukemia (AML).
In November 2016, Nohla raised $43.5 million in a Series A financing round, taking total investment in the company to $64.5 million.
See original here:
Nohla and UC Davis Ink Manufacturing Deal for Off-the-Shelf Donor Stem Cell Therapy - Genetic Engineering & Biotechnology News
Posted in Cell Therapy
Comments Off on Nohla and UC Davis Ink Manufacturing Deal for Off-the-Shelf Donor Stem Cell Therapy – Genetic Engineering & Biotechnology News
Potential of stem cell therapy to repair lung damage — ScienceDaily – Science Daily
Posted: March 28, 2017 at 4:41 am
Hindustan Times | Potential of stem cell therapy to repair lung damage -- ScienceDaily Science Daily A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic ... Study shows potential of stem cell therapy in repairing lung damage Stem Cell Therapy May Help Treat Lung Inflammation and Damage: Study Stem Cell therapy reduces lung damage; COPD and cystic fibrosis ... |
See more here:
Potential of stem cell therapy to repair lung damage -- ScienceDaily - Science Daily
Posted in Cell Therapy
Comments Off on Potential of stem cell therapy to repair lung damage — ScienceDaily – Science Daily